A Phase 2, Randomized, Double Blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients

Trial Profile

A Phase 2, Randomized, Double Blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2015

At a glance

  • Drugs Vancomycin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Methicillin-resistant Staphylococcus aureus infections
  • Focus Therapeutic Use
  • Sponsors Savara Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Feb 2015 Top-line results published in a Savara Pharmaceuticals media release.
    • 23 Feb 2015 Primary endpoint has been met (change from baseline at day 29 in the number of MRSA colony forming units (CFU) in sputum culture), according to a Savara Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top